NSE: CIPLA · BSE: 500087 · ISIN INE059A01026
Cipla Limited stock analysis
Cipla Limited ranks #2195 in the TickerSutra evidence-ranked universe with a score of 48/100 and 95% data confidence. The latest captured fundamentals show ROCE of 15.5%, quarterly sales growth of 2.3% and quarterly profit growth of -39.2%.Avoid / exit review
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.02×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Operating margin has compressed materially
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹21,763cr | ₹4,553cr | ₹2,547cr | 21.0% |
| 2023 | ₹22,753cr | ₹5,027cr | ₹2,833cr | 22.0% |
| 2024 | ₹25,774cr | ₹6,291cr | ₹4,154cr | 24.0% |
| 2025 | ₹27,548cr | ₹7,128cr | ₹5,269cr | 26.0% |
| 2026 | ₹28,163cr | ₹5,883cr | ₹3,862cr | 21.0% |
| TTM | ₹28,324cr | ₹5,297cr | ₹3,356cr | 19.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
RoutineTrading Window-XBRLNSE · 29 Sept 2026 · Structured filingCipla Limited has informed the Exchange about Closure of Trading Window
Cipla Limited has informed the Exchange about Closure of Trading Window
Open original XBRL sourceCipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated ....
RoutineChange in Directors/KMP/SMP/Auditor/RTANSE · 23 Sept 2026 · Structured filingCipla Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA
Cipla Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA
Open original XBRL sourcePlease find enclosed disclosure relating to the Change in SMP.
RoutineCipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015BSE · 18 Sept 2026Please find enclosed disclosure on ESG Rating.
MANAGEMENT COMMENTARY
Signals from filed documents
One key highlight for the quarter was the successful launch of generic Ventolin in the U.S. following regulatory approval, which was received last quarter. We have commenced commercial shipments with volumes expected to increase as the supply scales up.
One key highlight for the quarter was the successful launch of generic Ventolin in the U.S. following regulatory approval, which was received last quarter. We have commenced commercial shipments with volumes expected to increase as the supply scales up.
So, it will get substituted as the new pipeline kicks in with good healthy high margins. Ashish Adukia: And our EBITDA margin guidance is also predicated on the launches and the margin improvement. One question is on Ventolin, as well as one peptide product that you classify as a large product.
So, it will get substituted as the new pipeline kicks in with good healthy high margins. Ashish Adukia: And our EBITDA margin guidance is also predicated on the launches and the margin improvement. One question is on Ventolin, as well as one peptide product that you classify as a large product.
And subsequently, it was classified as VAI. FDA concluded a routine GMP inspection at Invagen facility in New York, which included with one Form 483 observation, which we are committed to addressing within the stipulated time line. We are also expecting the reinspection of our Indore facil ity to take place anytime soon.
Achin Gupta: No, we said we can launch as soon as we get approve. So, I think because we've not disclosed the name of the product, etc., we can't get into that exact detail, but we are awaiting approval. And as soon as we get approval, we are ready to launch.
We continue to look at M&A opportunities both for U.S. for certain differentiated products, but also Europe to develop some of this deep market. So, we've been fairly conservative on our approach on these acquisitions.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…